Russians love Putin's dustup with the West. But they've stopped spending money
Why rival discounters are vying for control of Family Dollar Stores
Twitter's head of product, Daniel Graf, must make the service more user-friendly without offending hard-core fans
Yale's Robert Shiller is sending up warning flares. It may be best to ignore him
To minimize flood chaos, turn the hospital upside down
Bayer is marketing Berocca as performance drink, but Australians know what it's really for
After years of effort, top B-schools still enroll only about 40 percent female MBAs
Advice for a small bed-and-breakfast trying to get on the map for international tourists
Founders: Dr. Daniel J. Abrams; Tom Anchordoquy, PhD; and Karen Stevens, PhD
VC Investment over the last four quarters: $21.5 million
Founded in 2005, this seven-person biopharmaceutical company develops drugs for the treatment of severe central nervous system diseases. In addition to VC funding, Sierra received about $230,000 in grants from the State of Colorado, the University of Colorado, and the Coleman Institute. As for the recession, its founders say the company will be keeping close tabs on the funding and partnership environment over the next two to three years, despite already being funded for drug development work for the next three years.
Key to startup success: "Be persistent in the development of your data and business model to enable you to create a financial model that has a high likelihood of helping patients and therefore is fundable by the investor community."